Myriad Genetics MYGN Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $829M-0.3% | $824.5M-1.6% | $825.3M+0.2% | $832.9M+3.8% | $831.3M+7.4% | ||
| $249M-0.1% | $247.9M-1.7% | $244.6M-3.7% | $246.2M-0.8% | $249.3M+3.2% | ||
| $580M-0.3% | $576.6M-1.5% | $580.7M+2.0% | $586.7M+5.9% | $582M+9.3% | ||
| 70%0.0pp | 69.9%0.0pp | 70.4%+1.2pp | 70.4%+1.4pp | 70%+1.2pp | ||
| $106.4M-7.7% | $106.8M-5.2% | $113.5M+11.8% | $113.8M+17.3% | $115.3M+26.6% | ||
| $285.2M+0.5% | $280.8M-1.2% | $284.1M-0.1% | $283M-1.3% | $283.9M-0.8% | ||
| $252.5M-7.1% | $256.8M-7.1% | $265.2M-6.4% | $266.5M-6.5% | $271.8M-4.3% | ||
| $968.9M+37.1% | $963.8M+36.0% | $1B+40.5% | $1B+36.3% | $706.5M-5.3% | ||
| $968.9M+37.1% | $963.8M+36.0% | $1B+40.5% | $1B+36.3% | $706.5M-5.3% | ||
| -$388.9M-212% | -$387.2M-214% | -$420.5M-263% | -$417.2M-168% | -$124.5M+46.6% | ||
| -46.9%-31.9pp | -47%-32.2pp | -51%-36.9pp | -50.1%-30.7pp | -15%+15.1pp | ||
| $13.8M+345% | $10.5M+275% | $6.8M+127% | $3.8M+18.8% | $3.1M+6.9% | ||
| $2.2M+57.1% | $1.8M+5.9% | $1.3M-38.1% | $1.2M-47.8% | $1.4M-41.7% | ||
| -$10.9M-354% | -$7.9M— | -$4.8M-500% | -$3.1M-343% | -$2.4M0.0% | ||
| -$399.8M-215% | -$395.1M-220% | -$425.3M-265% | -$420.3M-168% | -$126.9M+46.1% | ||
| $100K+100% | -$29.2M-849% | -$24.8M— | -$25.1M— | -$25.5M— | ||
| -$399.9M-294% | -$365.9M-187% | -$400.5M-245% | -$395.2M-155% | -$101.4M+56.8% | ||
| -48.2%-36.0pp | -44.4%-29.2pp | -48.5%-34.4pp | -47.4%-28.1pp | -12.2%+18.1pp | ||
| -$4.29-283% | -$3.93-179% | -$4.33-238% | -$4.28-139% | -$1.12+60.0% | ||
| -$4.29-283% | -$3.93-179% | -$4.33-238% | -$4.28-139% | -$1.12+60.0% | ||
| 371.9M+2.3% | 369.6M+2.1% | 367.6M+3.8% | 365.4M+5.9% | 363.5M+8.1% | ||
| 371.9M+2.3% | 369.6M+2.1% | 367.6M+3.8% | 365.4M+5.9% | 363.5M+8.1% | ||
| —— | $0+100% | -$5.33M-144% | -$10.65M-123% | -$15.98M-120% | ||
| $700K+200% | $800K-27.3% | $700K+600% | -$500K-350% | -$700K+63.2% | ||
| $829M-0.3% | $824.5M-1.6% | $825.3M+0.2% | $832.9M+3.8% | $831.3M+7.4% | ||
| $32.2M-31.9% | $35.2M-29.3% | $43.3M-12.2% | $43.5M-10.3% | $47.3M+4.6% | ||
| -$388.9M-212% | -$387.2M-214% | -$420.5M-263% | -$417.2M-168% | -$124.5M+46.6% | ||
| -$337.1M-422% | -$333.5M-436% | -$364.6M-571% | -$358.3M-274% | -$64.6M+63.1% | ||
| -$337.1M-422% | -$333.5M-436% | -$364.6M-571% | -$358.3M-274% | -$64.6M+63.1% | ||
| -40.7%-32.9pp | -40.4%-33.0pp | -44.2%-37.6pp | -43%-31.1pp | -7.8%+14.8pp | ||
| -$388.9M-212% | -$387.2M-214% | -$420.5M-263% | -$417.2M-168% | -$124.5M+46.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Myriad Genetics's revenue?
- Myriad Genetics (MYGN) generated $829.0M in revenue over the trailing twelve months, down 0.3% year over year.
- Is Myriad Genetics profitable?
- Myriad Genetics is not currently profitable: it reported a net loss of $399.9M over the trailing twelve months, a -48.2% net margin.
- What are Myriad Genetics's profit margins?
- Gross margin is 70.0% and operating margin is -46.9%, with a -48.2% net margin.
- What is Myriad Genetics's earnings per share?
- Myriad Genetics's diluted EPS over the trailing twelve months is $-4.29.
- Where does Myriad Genetics's income statement data come from?
- Every line is extracted from Myriad Genetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
